REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2021

Feb 11, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Decibel Therapeutics, Inc. (DBTX)
CIK: 0001656536
Period of Report: 2021-02-11

Reporting Person: REGENERON PHARMACEUTICALS, INC. (10% Owner)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series B Preferred Stock	$		Common Stock (989299)		Direct
Series C Preferred Stock	$		Common Stock (1108015)		Direct

Footnotes

F1: The Series B Preferred Stock and Series C Preferred Stock are convertible into shares of common stock of Decibel Therapeutics, Inc. ("Decibel") at any time pursuant to the terms of Decibel's Fourth Amended and Restated Certificate of Incorporation, as amended. The Series B Preferred Stock and the Series C Preferred Stock have no expiration date.

F2: The Series B Preferred Stock and the Series C Preferred Stock are convertible into shares of common stock of Decibel on an approximately one-for-0.079 basis, with any resulting fractional shares of common stock being rounded down to the nearest whole number. The reported number of shares of underlying common stock and the conversion ratio give effect to Decibel's one-for-5.3 reverse stock split, which became effective on February 5, 2021.